NO20030926L - Fremgangsmåte for fremstilling av hydrater av olanzapin og deres omdannelsetil krystallinske former av olanzapin - Google Patents

Fremgangsmåte for fremstilling av hydrater av olanzapin og deres omdannelsetil krystallinske former av olanzapin

Info

Publication number
NO20030926L
NO20030926L NO20030926A NO20030926A NO20030926L NO 20030926 L NO20030926 L NO 20030926L NO 20030926 A NO20030926 A NO 20030926A NO 20030926 A NO20030926 A NO 20030926A NO 20030926 L NO20030926 L NO 20030926L
Authority
NO
Norway
Prior art keywords
olanzapine
hydrates
conversion
preparation
crystalline forms
Prior art date
Application number
NO20030926A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030926D0 (no
Inventor
Robert Koprowski
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Publication of NO20030926D0 publication Critical patent/NO20030926D0/no
Publication of NO20030926L publication Critical patent/NO20030926L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20030926A 2000-08-31 2003-02-27 Fremgangsmåte for fremstilling av hydrater av olanzapin og deres omdannelsetil krystallinske former av olanzapin NO20030926L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN709CH2000 2000-08-31
IN711CH2000 2000-08-31
PCT/US2001/007258 WO2002018390A1 (en) 2000-08-31 2001-03-07 Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine

Publications (2)

Publication Number Publication Date
NO20030926D0 NO20030926D0 (no) 2003-02-27
NO20030926L true NO20030926L (no) 2003-04-24

Family

ID=26324874

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030926A NO20030926L (no) 2000-08-31 2003-02-27 Fremgangsmåte for fremstilling av hydrater av olanzapin og deres omdannelsetil krystallinske former av olanzapin

Country Status (12)

Country Link
EP (1) EP1313742A1 (pt)
JP (1) JP2004507548A (pt)
AU (1) AU2001243475A1 (pt)
BR (1) BR0114031A (pt)
CA (1) CA2420987A1 (pt)
CZ (1) CZ2003566A3 (pt)
HU (1) HUP0300875A3 (pt)
IL (1) IL154688A0 (pt)
NO (1) NO20030926L (pt)
RU (1) RU2003108745A (pt)
SK (1) SK2502003A3 (pt)
WO (1) WO2002018390A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002340328A1 (en) * 2001-10-29 2003-05-12 Janet I. Cord Olanzapine dihydrate-ii a process for its preparation and use thereof
AU2003243153A1 (en) * 2002-04-23 2003-11-10 Dr. Reddy's Laboratories Limited Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
AU2002251329A1 (en) * 2002-04-25 2003-11-10 Generics (Uk) Limited Novel crystalline forms of celecoxib and other compounds
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
US7297789B2 (en) 2002-05-31 2007-11-20 Sandoz, Inc. Process of preparation of olanzapine form I
SI21270A (sl) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
US7323459B2 (en) 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
DE602004014264D1 (de) 2003-12-22 2008-07-17 Teva Pharma Verfahren zur herstellung von olanzapin
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
AR047461A1 (es) * 2004-01-27 2006-01-18 Synthon Bv Formacion, purificacion y uso de n-formilolanzapina
EP1716154A1 (en) * 2004-02-19 2006-11-02 Neuland Laboratories Ltd Process for the preparation of olanzapine form 1 useful as antipsychotic drug
WO2005107375A2 (en) * 2004-05-06 2005-11-17 Matrix Laboratories Ltd Process for the preparation of olanzapine form-i
US8044196B2 (en) 2004-07-14 2011-10-25 Jubilant Organosys Limited Process for producing pure form of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
EP1781666A1 (en) * 2004-07-14 2007-05-09 Shasun Chemicals and Drugs Limited Improved process for making form i of olanzapine.
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
WO2006025065A1 (en) * 2004-08-31 2006-03-09 Lee Pharma Private Limited A process for the preparation of anhydrous olanzopine hydrochloride of form-1
WO2006027800A1 (en) * 2004-09-06 2006-03-16 Shasun Chemicals And Drugs Limited A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine
PL1838716T3 (pl) * 2005-01-05 2011-09-30 Lilly Co Eli Dihydrat embonianu olanzapiny
BRPI0608484E2 (pt) * 2005-03-21 2014-10-29 Reddys Lab Ltd Dr Processo de preparação da forma i cristalina de olanzapina
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2687143A1 (en) * 2007-05-15 2008-11-20 Generics [Uk] Limited Process for the purification of olanzapine
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
PT3466934T (pt) 2016-05-31 2024-04-30 Taiho Pharmaceutical Co Ltd Compostos de sulfonamida ou seus sais como inibidores da ribonucleótido-redutase para o tratamento de cancro
MX2020005478A (es) 2017-11-29 2020-08-27 Taiho Pharmaceutical Co Ltd Compuestos de sulfonamida y usos de los mismos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009229D0 (en) 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
CZ299247B6 (cs) * 1996-09-23 2008-05-28 Eli Lilly And Company Olanzapin dihydrát D

Also Published As

Publication number Publication date
HUP0300875A2 (hu) 2003-12-29
HUP0300875A3 (en) 2005-09-28
CA2420987A1 (en) 2002-03-07
NO20030926D0 (no) 2003-02-27
RU2003108745A (ru) 2005-01-10
JP2004507548A (ja) 2004-03-11
SK2502003A3 (en) 2004-03-02
BR0114031A (pt) 2003-09-09
WO2002018390A1 (en) 2002-03-07
EP1313742A1 (en) 2003-05-28
CZ2003566A3 (cs) 2004-01-14
IL154688A0 (en) 2003-09-17
AU2001243475A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
NO20030926D0 (no) Fremgangsmåte for fremstilling av hydrater av olanzapin og deres omdannelsetil krystallinske former av olanzapin
IS6829A (is) Ný kristölluð form atorvastatínhálfkalsíums og aðferðir til framleiðslu á þeim sem og nýjar aðferðir til að framleiða önnur form
AU2001255277A1 (en) Use of moving element to produce heat
NO20030844L (no) Fremgangsmåte for fremstilling av N-aryl-antranilinsyrer og derivater derav
EE200300103A (et) Kontratseptsioonimeetod ja kontratseptiivi manustatav vorm
NO20032518L (no) Fremgangsmåte for fremstilling av amlodipinmaleat
NO20013943L (no) Fremgangsmate for fremstilling av Citalopram
NO20024623D0 (no) Ny fremgangsmåte for fremstilling av kondensert imidazopyridinderivat og ny krystallform
PL367518A1 (pl) Kompozycja o kontrolowanym uwalnianiu i metoda jej wytwarzania
PT1432685E (pt) Hidratos cristalinos de derivados de anilida do acido nicotinico e de benzoilanilida
NO20024321D0 (no) Fremgangsmåte for fremstilling av krystallinsk form I av kabergolin
NO20015316L (no) Optimalisering av fermenteringsprosess
AU2001285325A1 (en) Use of threo-methylphenidate compounds to enhance memory
SG86468A1 (en) Production process of high-purity gypsum
NO20024527D0 (no) Krystallinsk form II av kabergolin
NO20040368L (no) Fremgangsmate til fremstilling og rensing av natriumhydrid
NO20020717L (no) Produksjon av dampavsatt silika
NO20035633D0 (no) Teknisk syntesemetode for fremstilling av tropenol
AU1396502A (en) Amorphous form of cell cycle inhibitor
NO20030515D0 (no) Fremgangsmåte for fremstilling av dinapsolin
NO20021118D0 (no) Fremgangsmåte for fremstilling av citalopram
NO20023577L (no) Fremgangsmåte for fremstilling av acetyl-amidinofenylalanyl- cykloheksylglycyl-pyridinioalaninamider
NO20023702D0 (no) Fremgangsmåte for fremstilling av 5-arylnikotinaldehyder
EE200300567A (et) Meetod amorfse naatrium-tsilastatiini valmistamiseks
NO20032297D0 (no) Fremgangsmåte for fremstilling av distamycinderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application